Why Clinical Trials Happen All Over the World: Globalization Explained
A trial for one drug might enroll patients in Boston, Beijing, and Brazil at the same time. That is not an accident, and it is not only about cutting costs. Global trials have become the standard way modern medicines are developed. About 80% of FDA-approved drugs include data from clinical trials conducted outside the United States, a figure the Clarity Clinical Solutions video on globalization cites as the norm rather than the exception.
Three reasons for going global
The video identifies three drivers. Speed comes first: recruiting patients in several countries at once fills a trial months faster than a single-country study. Diversity comes second: different populations can respond differently to a drug, and regulators want evidence the treatment works across ethnic groups, not just in one country. Cost comes third: running trials in some countries is significantly cheaper, which makes drug development more affordable overall.
Where do these trials happen? Historically, most research concentrated in the US and Western Europe. Today Eastern Europe, Asia, and Latin America are major locations, with China, India, and Poland among the most popular. Africa remains underrepresented, hosting less than 10% of global trials despite having about 17% of the world's population, though that is slowly changing as infrastructure improves.
The trade-offs between developed and developing countries
Developed countries offer mature regulatory agencies and rigorous standards, but trials are expensive and enrollment can be slow because so many studies compete for the same patients. Developing countries offer costs 40 to 60% lower per patient and faster enrollment, since fewer trials compete for patients. The trade-off is less mature regulatory systems, weaker infrastructure, and higher ethical risk. Sponsors have to balance cost and speed against regulatory risk and ethical responsibility on every site decision.
The complexity of running across borders
Global trials multiply complexity. Each country has its own approval process, ethics requirements, and reporting standards, and a single trial can span twenty or more countries simultaneously. Ethical concerns include the risk of exploitation in low-income countries, different standards of care, and language barriers in informed consent. Data quality is harder to hold constant when different labs use different equipment and data entry happens in many languages, which is why a centralized data management system is essential.
The framework that makes it work
The International Council for Harmonisation (ICH) exists to standardize clinical trial regulations globally. It was founded in 1990 by regulators and industry from the US, EU, and Japan. Its E6 good clinical practice guideline, first published in 1996, became the most widely adopted clinical trial standard in the world, and a modernized version, E6(R3), was released in 2023 (ICH efficacy guidelines, including E6 and E6(R3)). Harmonization does not mean identical regulations. It means the core ethical and scientific standards are aligned, so regulators can accept data from trials run anywhere.
Multiregional trials have their own guidance. ICH E17 sets out principles for planning and designing trials across regions so that results are acceptable to all participating regulators (FDA: ICH E17 guidance on multiregional clinical trials). European regulators apply the same good clinical practice standards through EMA requirements (EMA: good clinical practice).
The ethical questions that never go away
Globalization raises hard questions. When a trial runs in a low-income country, is it ethical to give a placebo when effective treatment exists in the sponsor's home country but is not available locally? This remains one of the most debated issues in research ethics. Informed consent across cultures is another: participants may speak different languages, or come from cultures where agreeing with a doctor is expected, so a signature on a translated form does not always mean genuine understanding. The World Medical Association's Declaration of Helsinki, the foundational ethics statement for medical research, requires that research be responsive to the health needs of the host community (WMA Declaration of Helsinki).
How sponsors choose countries
Four factors drive country selection. Disease prevalence, because the condition must be common enough to recruit quickly. The regulatory environment, since faster approval timelines get priority. Research infrastructure, because qualified investigators, accredited labs, and reliable systems are non-negotiable. And cost, which breaks ties when everything else is equal. The WHO frames the public-health side of trial planning, emphasizing that research should serve the populations that participate (WHO: clinical trials).
Local rules still apply on top of global standards
Harmonization does not erase local law. In Europe, the GDPR shapes how patient data is handled. In China, the Personal Information Protection Law restricts data transfers. In the US, HIPAA governs health information privacy. Sponsors design protocols that meet both the global standard and the most restrictive local requirement across all their trial countries.
What the pandemic proved
COVID-19 was a case study in what global research can achieve. The Pfizer and Moderna vaccine trials each enrolled more than 40,000 participants across four continents in under six months. Regulators coordinated reviews, ethics committees expedited approvals, and sites activated worldwide at once. The global approach delivered speed and evidence of effectiveness across diverse populations. The video's point: when the will exists, clinical research can move remarkably fast.
The future of global trials
Three directions stand out. More trials will move into Africa and Southeast Asia as infrastructure and regulatory capacity improve. Decentralized trials will let participants join from home using telemedicine, wearables, and local labs, making global reach easier. And artificial intelligence will help manage the complexity, predicting recruitment, automating data quality checks, and spotting safety signals across languages and regions. The ethical challenges will persist and need attention as trials reach new communities.
The bottom line
Global is the standard: about 80% of FDA-approved drugs include data from trials outside the US. The reasons are speed, diversity, and practicality. But ethics must lead. Every country added to a trial must meet the same standards for informed consent, independent review, and post-trial access. Speed and cost must never compromise ethics. Regulatory harmonization through ICH makes globalization possible, but local regulations still matter, and success means navigating both at once.
This article is based on the Clarity Clinical Solutions video "Why Clinical Trials Happen All Over the World: Globalization Explained." Watch it here: Why Clinical Trials Happen All Over the World: Globalization Explained
References
- Clarity Clinical Solutions video — the framework for this article: reasons for global trials, regional patterns, country selection, ethical questions, COVID-19 vaccine trials. https://www.youtube.com/watch?v=QFdmRHDD-2c
- ICH — Efficacy guidelines, including E6 good clinical practice and E6(R3). https://www.ich.org/page/efficacy-guidelines
- FDA — ICH E17 guidance on planning and designing multiregional clinical trials. https://www.fda.gov/media/108720/download
- WMA — Declaration of Helsinki: ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
- WHO — Clinical trials topic page. https://www.who.int/health-topics/clinical-trials
- EMA — Good clinical practice in human research. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-clinical-practice